Amplification Technology for Improved Genomic Sequencing

BioSkryb Genomics specializes in advanced genomic technologies that focus on single-cell analysis, which is crucial for understanding cellular heterogeneity and its implications for human health and disease. Their flagship technology, Primary Template-directed Amplification (PTA), allows for highly efficient whole genome amplification (WGA) from single cells, achieving over 95% genome recovery and uniform coverage. This method addresses the limitations of traditional amplification techniques, such as amplification bias and low accuracy, by utilizing a controlled, quasi-linear amplification process that minimizes errors and enhances variant calling sensitivity. PTA is integral to BioSkryb's ResolveDNA® and ResolveOME™ products, which enable simultaneous amplification of both genome and transcriptome from a single cell, facilitating comprehensive multiomic analysis.

In addition to PTA, BioSkryb offers the BaseJumper™ bioinformatics platform, designed to streamline data visualization and analysis for single-cell genomics. This platform supports researchers in uncovering complex molecular characteristics and enhances the understanding of gene-disease relationships. The combination of PTA and BaseJumper™ empowers scientists to conduct precise genomic studies, driving innovations in personalized medicine and cancer research. BioSkryb's technologies are positioned at the forefront of genomic exploration, providing tools that enhance the accuracy and efficiency of single-cell sequencing and analysis.

United States

BioSkryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

BioSkryb

Company Details